Current Management of Severe Refractory Asthma in Italy: Analysis of Real-World Data:

Global & Regional Health Technology Assessment

AntonellaPedrini¹ 

关键词: Burden of illness;    Costs;    Database analysis;    Prevalence;    Real world;    Severe asthma;   

DOI  :  10.5301/grhta.5000273

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

IntroductionSevere refractory asthma (SRA) occurs in asthma patients failing to achieve disease control despite high-intensity therapy, good adherence, and proper inhalation technique. Lack of disease control in asthma is associated with increased health care costs. Omalizumab, an anti-IgE monoclonal antibody, improves disease control in SRA patients by reducing the number of exacerbations. However, real-world evidence studies are needed to quantify the burden of SRA on health care systems. The aim of this study was to assess the current management of SRA in Italy by analyzing the prevalence of the disease and the economic impact of SRA patients.MethodsThis observational study retrospectively analyzed data concerning adult patients registered in an Italian health care system database with either a prescription of omalizumab or at least a prescription of high-dose systemic corticosteroids from 2013 to 2014.ResultsThe overall prevalence of SRA was 0.04%. SRA-related costs were equally distributed among 3 co...

【 授权许可】

CC BY